课题基金 / 基金详情

缺氧环境诱导的外泌体miR-133b调控HuR/Vav3影响乳头状甲状腺癌的转移机制研究

批准号:
81972543
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
伍波
依托单位:
学科分类:
肿瘤微环境
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
伍波

项目摘要

结项摘要

相似基金

相关文献

中文摘要
乳头状甲状腺癌(PTC) 发病率呈逐年上升趋势,多数患者预后良好。但晚期肿瘤出现侵袭和转移能力增强,传统治疗手段效果欠佳。课题组近期收集PTC 原位癌和转移癌分别做蛋白芯片和miRNA芯片检测,发现 HuR和Vav3 在转移癌中高表达,而miR-133b 低表达。为了模拟肿瘤缺氧微环境,体外缺氧诱导分泌外泌体,发现miR-133b在缺氧诱导的外泌体中低表达,并且促进PTC 细胞的迁移。课题组通过生物信息学分析和荧光素酶检测发现miR-133b调控HuR的3’UTR 以及染色质免疫共沉淀检测HuR 调控Vav3的表达。而过表达Vav3 能够激活Rac1/JNK 通路,促进PTC 细胞迁移。基于以上结果我们推测缺氧环境介导外泌体miR-133b通过调控HuR的表达,进而调控Vav3 /Rac1/JNK信号通路最终导致了PTC迁移、侵袭和转移,为探索PTC的发生发展提供重要的理论基础。
英文摘要
The incidence of papillary thyroid cancer (PTC) is increasing rapidly, and most patients have a good prognosis after treatment. Although most patients have a good prognosis when treated with traditional therapy, it is difficult to achieve satisfactory results in progress and metastatic tumour. The research team recently collected PTC tissue for protein chip and miRNA microarray examination and found that HuR and Vav3 are highly expressed in metastatic tumor, while miR-133b is lowly expressed. When hypoxia induced secretion of exosomes in vitro, it was found that miR-133b is underexpressed in hypoxia-induced exosomes and promotes migration of PTC cells. The bioinformatics analysis and luciferase assay showed that miR-133b regulates the 3'UTR of HuR and chromatin immunoprecipitation to detect the expression of Vav3 by HuR. Overexpression of Vav3 activates the Rac1/JNK pathway and promotes PTC cell migration. Based on the above results, we hypothesized that the hypoxic environment mediates the expression of HuR by exosome miR-133b, and then regulates the Vav3 /Rac1/JNK signaling pathway, which ultimately leads to the occurrence of PTC migration, invasion and metastasis.
甲状腺乳头状癌(Papillary thyroid cancer, PTC)的发病率在过去30年里在全球范围内呈上升趋势。肿瘤来源的外泌体与癌细胞的转移有关,存在于局部乏氧的肿瘤微环境中,通过在细胞间转移包括微小RNA (miRNA)在内的分子来介导细胞间的通讯。虽然miRNA已被证明可作为癌症诊断的非侵入性生物标志物,但缺氧诱导的肿瘤源性外泌体在PTC进展中的作用仍不清楚。在这里,我们使用R中的DESeq包研究了来自GEO数据集(GSE191117和GSE151180)的差异表达的miRNA表达谱,并确定了miR-221-3p作为癌基因在PTC发展中的新作用。体内外实验证明了缺氧PTC细胞来源的外泌体miR-221-3p在PTC中的作用机制。miR-221-3p在人PTC血浆外泌体、组织和PTC细胞系中表达上调。我们发现,在体外缺氧PTC细胞来源的外泌体-miR-221-3p促进了常氧PTC细胞的增殖,迁移,侵袭和EMT的发生,而抑制miR-221-3p则限制了PTC裸鼠移植瘤的生长。研究也发现了ZFAND5是miR-221-3p的靶基因。机制上,缺氧PTC细胞系来源的外泌体携带miR-221-3p通过调控ZFAND5促进PTC肿瘤发生。我们的发现进一步理解了与PTC进展相关的潜在机制,并确定了外泌体分泌的 mirR-221-3p可以作为PTC患者诊断和预后的潜在生物标志物。我们的研究也提示miR-221-3p抑制剂可能是PTC的潜在治疗策略。
国内基金
海外基金